Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping

被引:0
作者
M Beau-Faller
M Legrain
A-C Voegeli
E Guérin
T Lavaux
A-M Ruppert
A Neuville
G Massard
J-M Wihlm
E Quoix
P Oudet
M P Gaub
机构
[1] Laboratoire de Biochimie et de Biologie Moléculaire,
[2] Hôpital de Hautepierre,undefined
[3] Centre Hospitalier Universitaire de Strasbourg,undefined
[4] UMR7104,undefined
[5] Institut de Génétique et de Biologie Moléculaire (IGBMC),undefined
[6] Pôle de Pathologie Thoracique,undefined
[7] Service de Pneumologie,undefined
[8] Nouvel Hôpital Civil,undefined
[9] Centre Hospitalier Universitaire de Strasbourg,undefined
[10] Pôle de Biologie,undefined
[11] Laboratoire de Pathologie,undefined
[12] Hôpital de Hautepierre,undefined
[13] Centre Hospitalier Universitaire de Strasbourg,undefined
[14] Pôle de Pathologie Thoracique,undefined
[15] Service de Chirurgie Thoracique,undefined
[16] Nouvel Hôpital Civil,undefined
[17] Centre Hospitalier Universitaire de Strasbourg,undefined
来源
British Journal of Cancer | 2009年 / 100卷
关键词
non-small cell lung cancer; mutations; sensitivity; real-time PCR; PNA;
D O I
暂无
中图分类号
学科分类号
摘要
Non-small cell lung cancers (NSCLC), in particular adenocarcinoma, are often mixed with normal cells. Therefore, low sensitivity of direct sequencing used for K-Ras mutation analysis could be inadequate in some cases. Our study focused on the possibility to increase the detection of K-Ras mutations in cases of low tumour cellularity. Besides direct sequencing, we used wild-type hybridisation probes and peptide-nucleic-acid (PNA)-mediated PCR clamping to detect mutations at codons 12 and 13, in 114 routine consecutive NSCLC frozen surgical tumours untreated by targeted drugs. The sensitivity of the analysis without or with PNA was 10 and 1% of tumour DNA, respectively. Direct sequencing revealed K-Ras mutations in 11 out of 114 tumours (10%). Using PNA-mediated PCR clamping, 10 additional cases of K-Ras mutations were detected (21 out of 114, 18%, P<0.005), among which five in samples with low tumour cellularity. In adenocarcinoma, K-Ras mutation frequency increased from 7 out of 55 (13%) by direct sequencing to 15 out of 55 (27%) by clamped-PCR (P<0.005). K-Ras mutations detected by these sensitive techniques lost its prognostic value. In conclusion, a rapid and sensitive PCR-clamping test avoiding macro or micro dissection could be proposed in routine analysis especially for NSCLC samples with low percentage of tumour cells such as bronchial biopsies or after neoadjuvant chemotherapy.
引用
收藏
页码:985 / 992
页数:7
相关论文
共 348 条
[1]  
Adjei AA(2001)Blocking oncogenic Ras signalling for cancer therapy J Natl Cancer Inst 93 1062-1074
[2]  
Ahrendt SA(2001)Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung Cancer 92 1525-1530
[3]  
Decker PA(2008)MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort J Thorac Oncol 3 331-339
[4]  
Alawi EA(1991)Molecular themes in oncogenesis Cell 64 235-248
[5]  
Zhu Yr YR(2002)Trimodality treatment in Stage III nonsmall cell lung carcinoma: prognostic impact of K-ras mutations after neoadjuvant therapy Cancer 94 2055-2062
[6]  
Sanchez-Cespedes M(2004)Rapid detection of K-ras mutations in bile by peptide nucleic acid-mediated PCR clamping and melting curve analysis: comparison with restriction fragment length polymorphism analysis Cl Chemistry 50 481-489
[7]  
Yang SC(2005)Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes Br J Cancer 92 405-412
[8]  
Haasler GB(2008)High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies BMC Cancer 8 1-14
[9]  
Kajdacsy-Balla A(2008)Non-Small-Cell Lung Cancer Working Group Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting J Clin Oncol 26 983-994
[10]  
Demeure MJ(2005)Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 5900-5909